Posted by Michael Wonder on 05 Oct 2021
NICE recommends first treatment in two decades for sickle cell disease
5 October 2021 - Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today.
For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the NHS. Crizanlizumab (Adakveo, Novartis) is recommended by NICE as a treatment option for preventing recurrent sickle cell crises in people aged 16 or over.
More than 300 people a year are expected to receive the treatment via a managed access agreement, increasing to more than 450 people in subsequent years.
